RxSight Yönetim
Yönetim kriter kontrolleri 3/4
RxSight CEO'su Ron Kurtz, Jan2016 tarihinde atandı, in görev süresi 8.92 yıldır. in toplam yıllık tazminatı $ 3.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.6% maaş ve 79.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.05% ine doğrudan sahiptir ve bu hisseler $ 37.96M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 3.3 yıldır.
Anahtar bilgiler
Ron Kurtz
İcra Kurulu Başkanı
US$3.1m
Toplam tazminat
| CEO maaş yüzdesi | 20.6% |
| CEO görev süresi | 8.9yrs |
| CEO sahipliği | 2.1% |
| Yönetim ortalama görev süresi | 4.2yrs |
| Yönetim Kurulu ortalama görev süresi | 3.3yrs |
Son yönetim güncellemeleri
Recent updates
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Tazminat ve Piyasa: Ron 'nin toplam tazminatı ($USD 3.08M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.36M ).
Tazminat ve Kazançlar: Ron şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Ron Kurtz (61 yo)
8.9yrs
Görev süresi
US$3,081,597
Tazminat
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as President and Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 20...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 8.9yrs | US$3.08m | 2.05% $ 38.0m | |
| Co-President & Chief Commercial Officer | 9.5yrs | US$1.65m | 0.76% $ 14.1m | |
| Co-President & Chief Financial Officer | 7.8yrs | US$1.89m | 0.076% $ 1.4m | |
| Co-President & Chief Operating Officer | 5.5yrs | US$1.89m | 0.11% $ 2.0m | |
| Vice President of Accounting & Finance | no data | Veri yok | Veri yok | |
| Chief Technology Officer | no data | Veri yok | Veri yok | |
| Vice President of Investor Relations | 1.1yrs | Veri yok | Veri yok | |
| Senior VP of Sales of North America | less than a year | Veri yok | Veri yok | |
| Senior VP of Marketing & Professional Relations | 2.9yrs | Veri yok | Veri yok | |
| Vice President of Human Resources | 9.3yrs | Veri yok | Veri yok | |
| Executive VP of Manufacturing & Commercial Operations | 2.9yrs | Veri yok | Veri yok | |
| Executive VP of Clinical & Regulatory Affairs | 2.8yrs | Veri yok | Veri yok |
4.2yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim: RXST 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 8.8yrs | US$3.08m | 2.05% $ 38.0m | |
| Director | 8.1yrs | US$204.98k | 0.11% $ 2.1m | |
| Independent Director | 3.3yrs | US$209.98k | 0.062% $ 1.2m | |
| Independent Director | 9.5yrs | US$209.98k | 0.090% $ 1.7m | |
| Independent Chairman of the Board | 9.9yrs | US$257.48k | 1.33% $ 24.6m | |
| Independent Director | 2.9yrs | US$204.98k | 0.057% $ 1.0m | |
| Independent Director | 3.3yrs | US$214.98k | 0.062% $ 1.2m | |
| Independent Director | 3.3yrs | US$212.48k | 0.062% $ 1.2m | |
| Independent Director | 3yrs | US$199.98k | 0.0048% $ 89.4k |
3.3yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: RXST 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).